Opioid Use Disorder Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The opioid use disorder market was valued at USD 2.66 Billion in 2025. It is poised to grow at a CAGR of 10.00% during the forecast period of 2026-2035, and reach USD 6.90 Billion by 2035. The market growth is driven by rising opioid addiction cases, increasing awareness of treatment options, expanding medication-assisted therapies, supportive government initiatives, and advancements in long-acting treatment formulations globally.

Latest News on the Opioid Use Disorder Market (2026)

• In April 2026, Indivior presented ASAM data showing SUBLOCADE improved treatment retention and reduced overdose risk in opioid use disorder patients.
• In November 2025, Indivior reported AMCP Nexus real-world evidence showing monthly buprenorphine injections improved adherence and reduced healthcare utilization in opioid use disorder treatment.
• In February 2025, FDA approved SUBLOCADE label changes enabling rapid initiation after single dose and flexible injection sites for opioid use disorder therapy.

Key Market Trends and Insights

• Based on drug type, Buprenorphine segment is expected to dominate the market as it accounted for about 59% market share in the historical period.
• Based on route of administration, the oral segment is anticipated to lead the market.
• Based on region, North America is expected to dominate as it accounted for about 68% market share in the historical period.

Market Size and Forecast

• Market Size (2025): USD 2.66 Billion
• Projected Market Size (2035): USD 6.90 Billion
• CAGR (2026-2035): 10.00%

Opioid Use Disorder Market Overview

The opioid use disorder market is expanding due to rising global opioid addiction cases, increasing awareness of treatment options, and growing adoption of medication-assisted therapies. Expansion of healthcare access programs and supportive government initiatives are further driving demand. Advancements in long-acting formulations, digital therapeutics, and integrated care approaches are improving treatment adherence and outcomes across patient populations globally. The market reached a value of approximately USD 2.66 Billion in 2025.

Opioid Use Disorder Market Growth Drivers

Increasing Regulatory Approvals and Product Innovation Accelerating the Market Expansion

Rising opioid dependence cases and increasing need for faster initiation of treatment are key factors driving innovation in medication-assisted therapies. These drivers are strengthening regulatory advancements in long-acting buprenorphine formulations. For instance, in February 2025, the FDA approved label changes for Indivior’s SUBLOCADE, enabling rapid initiation after a single dose and expanding injection sites to improve treatment flexibility. This development is expected to enhance adoption of medication-assisted treatment in the forecast period.

Opioid Use Disorder Market Trends

Key trends shaping the market include rising adoption of medication-assisted therapy, long-acting formulations, and integration of digital treatment solutions.

Long-Acting Buprenorphine Innovations Driving the Market Development

Growing need for improved adherence and reduced relapse rates in opioid use disorder is driving innovation in long-acting injectable therapies. These factors support the development of extended-release formulations globally. For instance, in November 2025, Indivior presented real-world evidence at AMCP Nexus 2025 showing that monthly SUBLOCADE injections improved treatment retention and reduced healthcare utilization among patients with opioid use disorder. This development is expected to strengthen adoption of long-acting injectable therapies in the forecast period.

Opioid Use Disorder Market Segmentation

Market Breakup by Drug Type

• Buprenorphine
• Methadone
• Naltrexone
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Breakup by Country

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Opioid Use Disorder Market Share

Buprenorphine Segment Likely to Dominate the Market by Drug Type

The buprenorphine segment is expected to dominate the market as it accounted for about 59% revenue share in the historical period. Rising opioid dependence cases, increasing preference for medication-assisted treatment, and supportive regulatory frameworks are driving segment growth. Expanding use of opioid addiction treatment therapies is further enhancing patient outcomes and strengthening adoption across healthcare systems globally.

Opioid Use Disorder Market Analysis by Region

North America is expected to dominate as it accounted for about 68% share in the historical period. High prevalence of opioid misuse, strong healthcare infrastructure, and extensive treatment access programs are key growth drivers. Increasing adoption of medication-assisted treatment approaches further supports regional leadership and improves long-term recovery outcomes across healthcare settings.

Leading Players in the Opioid Use Disorder Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Indivior Pharmaceuticals, Inc.

Founded in 2014 and headquartered in Richmond, Virginia, USA, Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on addiction treatment therapies. Its portfolio includes SUBLOCADE and SUBOXONE for opioid use disorder management. The company plays a significant role in the opioid use disorder market through advancements in long-acting buprenorphine formulations, improving treatment adherence, relapse prevention, and long-term recovery outcomes.

Orexo US, Inc.

Headquartered in Morristown, New Jersey, USA, Orexo US, Inc. specializes in pharmaceutical treatments for opioid dependence and pain management. The company’s portfolio includes ZUBSOLV, a buprenorphine and naloxone sublingual tablet for opioid use disorder treatment. Orexo contributes to the opioid use disorder market by expanding access to medication-assisted treatment solutions and supporting improved patient compliance and recovery outcomes.

Titan Pharmaceuticals Inc.

Founded in 1992 and headquartered in South San Francisco, California, USA, Titan Pharmaceuticals Inc. develops long-term drug delivery technologies for chronic conditions. Its portfolio includes Probuphine, a subdermal implant delivering continuous buprenorphine therapy for opioid dependence. The company contributes to the opioid use disorder market through innovative implant-based treatment approaches that support sustained drug delivery and improved treatment adherence.

Viatris Inc.

Established in 2020 and headquartered in Canonsburg, Pennsylvania, USA, Viatris Inc. is a global healthcare company offering a broad portfolio of branded and generic pharmaceuticals. The company provides therapies used in addiction management and opioid dependence treatment. Viatris contributes to the opioid use disorder market by improving access to affordable treatment options and supporting the expansion of medication-assisted therapies globally.

Other key players in the market include Hikma Pharmaceuticals Plc, Braeburn Pharmaceuticals, Inc., Pear Therapeutics, Inc., Eli Lilly and Company, Alkermes Plc, and Camurus AB.

Key Questions Answered in the Opioid Use Disorder Market Report

• What was the opioid use disorder market value in 2025?
• What is the opioid use disorder market forecast outlook for 2026-2035?
• What major factors aid the demand for the opioid use disorder market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major opioid use disorder market trends?
• Which drug type are expected to dominate the market segment?
• Which route of administration are expected to dominate the market segment?
• Which distribution channel are expected to dominate the market segment?
• Who are the key players in the opioid use disorder market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?